Gencor, a supplier of branded ingredients, has reported positive results on improving sleep measures in healthy adults with Levagen+ supplementation in a recently published study in Sleep Science and Practice. The study assessed the efficacy of dispersible Palmitoylethanolamide – PEA (Levagen+) as a sleep aid for adults with disturbed sleeping patterns.
103 healthy adults 18 years or older participated in the eight-week, randomised, double-blind, placebo-controlled study, which compared the efficacy of a 350 mg dose of Levagen+ PEA to placebo as a sleep aid. Participants received either treatment or placebo orally, daily, and with water one hour prior to sleep for the duration of the study. Sleep quality and quantity were measured using wrist actigraphy, a sleep diary and questionnaires.
The results indicated supplementation was associated a significantly reduced amount of time to fall asleep in individuals with sleep latency issues. Additionally, the supplementation group reportedly showed an improved time upon waking to feel fully awake which researchers said was “of particular interest, as sleep inertia and daytime grogginess is a common side effect of many pharmaceutical options for the treatment of sleep disturbance.”
“We are extremely pleased by the results from the PEA group reporting falling asleep faster and waking up the next day feeling more alert and awake without the grogginess and other cognitive impairments,” said Chase Shryoc, VP of Sales & Business Development for Gencor. “It is encouraging to see the efficacy of Levagen+ as an effective sleep aid.”
The ingredient is powered by LipiSperse, Pharmako Biotechnologies’ cold water dispersion technology, which has been shown to increase the absorption of PEA vs. standard PEA, Gencor says.
The product can be formulated into effervescent tablets, RTD shots, functional foods, functional beverages, and gummies and more.
